LRMR
NASDAQ
US
Larimar Therapeutics, Inc. - Common Stock
$4.79
▲ +$0.11
(+2.35%)
Vol 994K
2
Quality Score
fail
Rev ✗
NI ✗
>IPO ✗
Mkt Cap
$326.1M
ROE
-91.8%
D/E
0.00
Beta
1.03
52W
$2–$5
Wall Street Consensus
17 analysts · Apr 20269
Strong Buy
7
Buy
1
Hold
0
Sell
0
Strong Sell
94.1%
Buy Rating
Price Chart
Similar Stocks
EIKN
Eikon Therapeutics Inc
CBIO
Crescent Biopharma Inc
$164.8M
ZURA
Zura Bio Ltd
$340.7M
UPB
Upstream Bio Inc
$1.5B
RIGL
Rigel Pharmaceuticals Inc
P/E 6.9
$777.4M
TRDA
Entrada Therapeutics Inc
$392.9M
VSTM
Verastem Inc
$581.5M
LYEL
Lyell Immunopharma Inc
$653.9M
FDMT
4D Molecular Therapeutics Inc
$428.5M
IMMX
Immix Biopharma Inc
$275.6M
Earnings
Beat rate: 20.0%| Quarter | EPS Est | EPS Act | Surprise |
|---|---|---|---|
| Dec 2025 | $-0.52 | $-0.73 | $-0.21 |
| Sep 2025 | $-0.41 | $-0.61 | $-0.20 |
| Jun 2025 | $-0.49 | $-0.41 | +$0.08 |
| Mar 2025 | $-0.43 | $-0.46 | $-0.03 |
Fundamentals Trend
| Metric | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | -62.9% | -52.5% | -62.9% | -62.9% | -91.8% | -91.8% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — |
| D/E Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Current Ratio | 5.46 | 7.48 | 5.46 | 5.46 | 4.06 | 4.06 |
Key Ratios
ROA (TTM)
-74.6%
P/B
1.4
EPS (TTM)
$-1.93
CF/Share
$-0.75
52W High
$5.37
52W Low
$1.61
$1.61
52-Week Range
$5.37
How does LRMR compare to Biotechnology peers?
Peer group: Micro-cap Biotechnology (All) · 528 companies
LRMR valuation vs Biotechnology peers
P/E ratio
—
▼
0%
below
peers
(18.8)
vs Peers
vs Industry
Undervalued
P/S ratio
—
▼
0%
below
peers
(12.9)
vs Peers
vs Industry
Overvalued
P/B ratio
1.4
▼
42%
below
peers
(2.5)
vs Peers
vs Industry
Undervalued
Div yield
—
▼
0%
below
peers
(0.0%)
vs Peers
vs Industry
Low yield
LRMR profitability vs Biotechnology peers
ROE
-91.8%
▼
36%
below
peers
(-67.3%)
vs Peers
vs Industry
Weak
Net margin
—
▼
0%
below
peers
(-286.8%)
vs Peers
vs Industry
Top tier
Gross margin
—
▼
0%
below
peers
(78.6%)
vs Peers
vs Industry
In line
ROA
-74.6%
▼
60%
below
peers
(-46.7%)
vs Peers
vs Industry
Weak
LRMR financial health vs Biotechnology peers
D/E ratio
0.0
▼
0%
below
peers
(0.0)
vs Peers
vs Industry
Low debt
Current ratio
4.1
▼
9%
below
peers
(4.4)
vs Peers
vs Industry
In line
Beta
1.0
▲
6%
above
peers
(1.0)
vs Peers
vs Industry
Less volatile
LRMR fundamentals radar
LRMR
Peer median
Industry
LRMR profitability vs leverage
Bubble size = market cap · X = net margin · Y = D/E ratio
LRMR vs peers: key metrics
Latest News
No related news yet